Ocugen reports positive trial data and $115M convertible notes, extending cash runway into 2028.

Ocugen announced positive 12-month data from its OCU410 Phase 2 trial showing significant reduction in lesion growth for geographic atrophy, supporting a Phase 3 trial planned for late 2026. The company completed enrollment for key trials in retinitis pigmentosa and Stargardt disease, aiming for Biologics License Application submissions by 2027. Ocugen also priced a $115 million convertible senior notes offering, expected to extend its cash runway into 2028 after retiring higher-interest debt. These developments position Ocugen for potential regulatory approvals and commercialization of its gene therapies targeting blindness diseases.